News Channels

21 Oct 2017 Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology
21 Oct 2017 Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis
21 Oct 2017 uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018
21 Oct 2017 DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age
20 Oct 2017 DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
20 Oct 2017 Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
20 Oct 2017 Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
19 Oct 2017 AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris
19 Oct 2017 Roivant Sciences Enters into Development Partnership with AstraZeneca
19 Oct 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
19 Oct 2017 Biscayne Neurotherapeutics Reports Successful Phase 1b Clinical Trial Results For Its Novel Antiepileptic Agent
19 Oct 2017 Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a
19 Oct 2017 Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia
19 Oct 2017 Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines
19 Oct 2017 Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda
19 Oct 2017 Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)
19 Oct 2017 Tyme’s SM-88 Demonstrates Prolonged Overall Survival in Metastatic Cancer Patients Across Multiple Subgroups
19 Oct 2017 OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
19 Oct 2017 Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
19 Oct 2017 Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top